Affiliation: Institute of Cancer Research
- The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expressionT Eisen
Eukaryotic Transcription Laboratory, Marie Curie Research Institute, Oxted, Surrey, UK
Oncogene 11:2157-64. 1995..The potential role of Brn-2/N-Oct3 in melanocyte differentiation and gene expression is discussed...
- Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinomaJ S Waters
Royal Marsden Hospital, London and Sutton, UK
Br J Cancer 91:1763-8. 2004..This combination of gemcitabine and capecitabine has modest activity in immunotherapy-refractory metastatic renal carcinoma with manageable toxicity...
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisT Eisen
Royal Marsden Hospital, Downs Road, Surrey SMT 5PT, UK
Br J Cancer 95:581-6. 2006..i.d.). Ongoing trials in advanced melanoma are evaluating sorafenib combination therapies...
- The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesotheliomaE Andreopoulou
Lung Unit, Royal Marsden Hospital, Surrey, UK
Ann Oncol 15:1406-12. 2004..We have analysed prospectively collected data to evaluate a frequently used palliative chemotherapy regimen...
- Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II studyM J Allen
Royal Marsden Hospital, London, UK
Br J Cancer 83:980-5. 2000..It is of particular interest that this regimen appears to have high activity in fit patients with poor prognostic features...
- Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II studyM E R O'Brien
Royal Marsden Hospital and Kent Cancer Centre, Sutton, Surrey, UK
Ann Oncol 15:921-7. 2004..Vinorelbine and carboplatin are both active agents in the treatment of non-small-cell lung cancer (NSCLC). Vinorelbine has recently been developed in an oral formulation, which is as active as the intravenous (i.v.) form...
- TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysisA Matakidou
Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5NG, UK
Mutagenesis 18:377-85. 2003..Additional well-designed studies based on sample sizes commensurate with the detection of small genotypic risks may allow a more definitive conclusion...
- Systematic review of the relationship between family history and lung cancer riskA Matakidou
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
Br J Cancer 93:825-33. 2005..The limitations of the currently published epidemiological studies to infer genetic susceptibility are discussed...
- Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancerT Eisen
Department of Medicine, Royal Marsden Hospital, London, UK
Br J Cancer 82:812-7. 2000..No patients developed WHO grade 3 or 4 toxicity. Further studies evaluating the use of Thalidomide at higher doses as a single agent for advanced renal cancer and in combination with biochemotherapy regimens are warranted...
- Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancerS A Sohaib
Department of Imaging, Royal Marsden Hospital, London, UK
Br J Radiol 82:632-9. 2009..Whole-body MRI is a more sensitive method for detection of bone metastases in renal cancer than bone scintigraphy, and also allows the assessment of soft-tissue disease...
- Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?P J Ross
Lung Unit, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK
Br J Cancer 90:1905-11. 2004..03, RR=1.92) and an independent predictor of progression-free survival in patients with SCLC (P=0.01, RR=1.43). In conclusion, weight loss as a symptom of lung cancer predicts for toxicity from treatment and shorter survival...
- Survival from lung cancer in England and Wales up to 2001Y K Zee
Department of Oncology, University of Cambridge, Box 193 Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, Cambridge, UK
Br J Cancer 99:S43-6. 2008
- Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosisA Matakidou
Section of Cancer Genetics, Institute of Cancer Research, Surrey, UK
Br J Cancer 96:1904-7. 2007....
- Prognostic factors for renal cell carcinomaD Furniss
YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, United Kingdom
Cancer Treat Rev 34:407-26. 2008..Prospective validation of such integrated prognostic models will be essential...
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander M M Eggermont
Erasmus University Medical Center, Rotterdam, Netherlands
Lancet 372:117-26. 2008..Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability...
- Prognostic significance of folate metabolism polymorphisms for lung cancerA Matakidou
Section of Cancer Genetics, Institute of Cancer Research, Brookes Lawley Building, Sutton, Surrey SM2 5NG, UK
Br J Cancer 97:247-52. 2007..36; 1.06-1.75). While there is evidence that variation in the folate metabolism genes may influence prognosis from lung cancer, current data are insufficiently robust to distinguish individual patient outcome...
- Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentationU Khalid
Division of Medicine, Imperial College London, Fulham Road, London, SW10 9NH, UK
Support Care Cancer 15:39-46. 2007..The effectiveness of treatment is impaired in patients with weight loss. The aetiology of this weight loss is complex and poorly characterised. Decreased calorie intake may be important. The reasons for decreased intake are unknown...
- Patient selection for palliative whole-brain radiotherapy based on RTOG recursive partitioning analysisK Harrington
Clin Oncol (R Coll Radiol) 17:128. 2005
- Mucosal malignant melanoma of the head and neck: the Marsden experience over half a centuryN W Yii
Head and Neck Unit, The Royal Marsden NHS Trust, London, UK
Clin Oncol (R Coll Radiol) 15:199-204. 2003..Adding radiotherapy to surgery in tumours that could be radically excised did not confer any statistically significant advantage in reducing local recurrence or improving survival...
- The treatment of advanced renal cell cancer with high-dose oral thalidomideJ Stebbing
Department of Medical Oncology, The Royal Marsden Hospital, London SW3 6JJ, UK
Br J Cancer 85:953-8. 2001..Toxicities were of sufficient clinical significance for use of a lower and well tolerated dose of 400 mg in currently accruing studies...